Early Postoperative Intervention in Gastric Cancer Patients

Enrolling by invitation · Not applicable

Conditions studied: Gastric Cancer (GC), Postoperative Recovery

In brief

This study was conducted by Qilu Hospital and five other renowned medical centers, aiming to evaluate the impact of early structured postoperative intervention on quality of life and prognosis in patients with gastric cancer after neoadjuvant therapy.

Key facts

Study ID

NCT07444099

Run by

Qilu Hospital of Shandong University

People needed

264

Starts

2026-02-10

Expected to finish

2027-06-30

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 years;
• Histologically confirmed adenocarcinoma by preoperative pathology;
• Completed preoperative neoadjuvant therapy without obvious immune-related adverse events (irAEs);
• Patients with ycT3-4N+Mx disease deemed surgically resectable based on evaluation by gastroscopy, CT, PET-CT, and other imaging modalities;
• Signed informed consent and voluntary participation in this study;
• Standard ERAS (Enhanced Recovery After Surgery) management during the - perioperative period, with postoperative hospital stay ≤7 days.

You may not qualify if…

• Patients with central nervous system diseases or psychiatric disorders;
• Patients with severe diseases of other organ systems;
• Patients with recurrent infectious diseases or severe comorbidities;
• Patients requiring synchronous surgery for other diseases;
• Patients undergoing emergency surgery;
• Patients who developed any complication during hospitalization.

Where it is running

• Qilu Hospital of Shandong University — Jinan, Shandong, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.